A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer
| Status: | Archived |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | September 2010 |
| End Date: | September 2015 |
A Multi-Institutional Phase II Study Evaluating Surrogate Biomarkers of Response to Short Term Oral Vorinostat and Tamoxifen in Women With Newly Diagnosed Breast Cancer
This research study is designed to look at the effects of the combination of vorinostat
(Suberoylanilide Hydroxamic Acid or Zolinza) and tamoxifen on breast cancer tissue. The
investigators will do this by comparing tissues from the original breast biopsy to tissues
obtained after taking vorinostat and tamoxifen for 2 weeks.
Key eligibility criteria include:
- Newly diagnosed invasive breast cancer awaiting surgery or neoadjuvant (preoperative)
treatment
- No use of hormone contraceptives or replacement therapy within 30 days prior to the
diagnostic breast cancer biopsy (unless willing to have an additional biopsy prior to
starting the study)
- No prior or current use of any therapy to treat the current breast cancer.
We found this trial at
1
site
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The name Johns Hopkins has become synonymous...
Click here to add this to my saved trials
